首页> 外文期刊>Journal of proteomics >Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines
【24h】

Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines

机译:无标记磷酸化蛋白质组学的可行性及其在结直肠癌细胞系基线信号转导中的应用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Robust phosphopeptide enrichment methods with minimal fractionation are required to profile signaling network analysis in cancer cell lines and tissues. We assessed performance of single-shot LC-MS/MS label-free phosphoproteomics using TiOx-based phosphopeptide enrichment and report phosphopeptide identification reproducibility (75.8%), depth of identification (6014-6150 phosphopeptides) and reproducibility of label-free quantification (CV 17.8%). Subsequently, we have profiled the baseline global phosphorylation of 8 colorectal cancer (CRC) cell lines representing different CRC prognostic subtypes. Global single-shot phosphoproteomics can distinguish CRC subtypes previously identified by transcriptomics and identifies signaling proteins and processes associated with the CCS3 poor prognosis subtype. Data are available via ProteomeXchange with identifiers PXD001546 and PXD001550.
机译:在癌细胞系和组织中分析信号网络分析需要鲁棒的磷酸肽富集方法和最小限度的分离。我们使用基于TiOx的磷酸肽富集评估了单次LC-MS / MS无标记磷酸化蛋白质组学的性能,并报告了磷酸肽鉴定的可重复性(75.8%),鉴定深度(6014-6150磷酸肽)和无标记定量的可重复性(CV) 17.8%)。随后,我们概述了代表不同CRC预后亚型的8种结直肠癌(CRC)细胞系的总体基线磷酸化。整体单发磷酸化蛋白质组学可以区分先前由转录组学鉴定的CRC亚型,并鉴定与CCS3预后不良亚型相关的信号蛋白和过程。数据可通过ProteomeXchange获得,其标识符为PXD001546和PXD001550。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号